Loading...
XKRX
003060
Market cap17mUSD
Jul 10, Last price  
2,085.00KRW
1D
4.25%
1Q
-44.59%
Jan 2017
-89.53%
Name

Aprogen Biologics Inc

Chart & Performance

D1W1MN
XKRX:003060 chart
P/E
—
P/S
0.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-9.97%
Rev. gr., 5y
6.55%
Revenues
73.23b
+8.68%
17,117,086,00021,137,045,00062,227,816,00016,689,083,00050,122,955,34033,769,678,25029,543,262,23033,092,222,03040,324,275,48044,122,492,68046,100,951,70045,395,389,40050,903,820,55053,319,976,20056,481,701,59065,190,359,33087,363,627,71267,378,141,00073,226,140,000
Net income
-170.33b
L+62.25%
-10,496,595,000-5,489,801,000-8,097,501,000-704,422,000-4,560,115,000-24,870,962,000-20,852,021,000-3,887,364,7402,760,674,900-3,917,714,760-16,364,749,000-1,215,412,540-3,466,524,12018,917,569,9608,102,570,3705,583,620,100-118,269,720,510-104,978,892,000-170,330,530,000
CFO
-38.23b
L+23.35%
-4,773,709,000-3,461,909,000-4,994,895,000247,922,000-3,895,277,730-1,649,487,870-1,701,829,640-6,917,181,5701,847,053,050449,980,360-8,927,787,2801,331,380,770713,734,0208,088,157,750-6,226,540,19025,728,188,300-33,650,775,380-30,996,493,000-38,232,647,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aprogen Biologics, Inc. specializes in the production and distribution of pharmaceutical goods. The company's activities are structured across two main segments: Pharmaceutical and Bio. Its Pharmaceutical division supplies synthetic medicines, encompassing treatments for the circulatory, central nervous, and digestive systems, alongside antibiotics. Concurrently, the Bio division is dedicated to developing and manufacturing biopharmaceuticals. Aprogen Biologics was established on December 3, 1960, and its corporate headquarters are situated in Seoul, South Korea.
URL
http://www.aprogen-pharm.com/
IPO date
Oct 19, 1984
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT